MAR-ATENOLOL 50 MG
ATENOLOL : 50 MG · DIN 02371987 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-ATENOLOL?
MAR-ATENOLOL 50 MG contains ATENOLOL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02371987, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-ATENOLOL used for?
Mild or moderate hypertension; long-term management of angina pectoris due to ischemic heart disease. Not for emergency treatment of hypertensive crises.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02371987 |
|---|---|
| Brand name | MAR-ATENOLOL |
| Generic / active ingredient | ATENOLOL : 50 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB03 ATENOLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Oct-2012 |
| Original market date | 2012-10-22 00:00:00 |
How is it administered?
Hypertension: Initial 50 mg daily, may increase to 100 mg. Angina: Initial 50 mg daily, may increase to 100 mg daily or 50 mg twice daily. Max 200 mg/day. Adjust for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentions "STORAGE, STABILITY AND DISPOSAL" but content is missing). Typically 15-30°C for such products.
How is it supplied?
HDPE bottles of 100 and 500 tablets; PVC/Al Foil Unit Dose Blister packs of 10 (Cartons of 30 tablets).
Contraindications
Hypersensitivity; sinus bradycardia; 2nd/3rd degree A-V block; sick sinus syndrome; right ventricular failure; uncontrolled heart failure; cardiogenic shock; hypotension; severe peripheral arterial disorders.
Warnings and precautions
Abrupt cessation can exacerbate angina or cause MI. Use caution in heart failure, 1st degree heart block, bronchospastic disease, diabetes (masks hypoglycemia), and hyperthyroidism.
Is ATENOLOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AB03 ATENOLOL. 28 of 87 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ATENOL TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00773697 |
| APO-ATENOL TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00773689 |
| ATENOLOL | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828793 |
| ATENOLOL | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238318 |
| ATENOLOL | 25 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02326701 |
| ATENOLOL | 25 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02541564 |
| ATENOLOL | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828807 |
| ATENOLOL | 50 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238316 |
| JAMP-ATENOLOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367572 |
| JAMP-ATENOLOL | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367556 |
Who else supplies ATENOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATENOLOL appears in 359 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.